avipendekin pegol (NKTR-255) / Nektar Therap 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   67 News 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
avipendekin pegol (NKTR-255) / Nektar Therap
NCT05664217: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Terminated
2/3
15
US
NKTR-255 at 1.5 µg/kg, Polymer-conjugated interleukin (IL)-15 Receptor Agonist, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg, Placebo Comparator
Nektar Therapeutics
Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
05/24
08/24
2021-003669-36: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Not yet recruiting
2
280
Europe
BAVENCIO, sacituzumab govitecan, MSB0010718C, IMMU-132, M6223, NKTR-255, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, BAVENCIO, Trodelvy
Merck Healthcare KGaA, MERCK KGAA, Merck Healthcare KGaA
Advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy., Bladder cancer, Diseases [C] - Cancer [C04]
 
 
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
06/25
07/26
RESCUE, NCT05632809: REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors

Recruiting
2
39
US
NKTR-255, Durvalumab
M.D. Anderson Cancer Center, Nektar Therapeutics
Lung Cancer
12/25
12/27
2021-002177-25: A study on NKTR-255 in combination with Cetuximab as salvage treatment for Solid Tumors Estudio sobre NKTR-255 en combinación con Cetuximab como tratamiento de rescate para tumores sólidos.

Not yet recruiting
1/2
78
Europe
NKTR-255, cetuximab, NKTR-255, Lyophilisate for solution for infusion, Solution for infusion, Erbitux
Nektar Therapeutics, NEKTAR THERAPEUTICS, Nektar Therapeutics
Relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC) Carcinoma escamoso de cabeza y cuello (CECC) o carcinoma colorrectal (CCR) recidivante o resistente (R/R), Head and neck squamous cell cancer or colorectal cancer which has spread to other part of body Cáncer epidermoide de cabeza y cuello o cáncer colorrectal que se ha extendido a otra parte del cuerpo, Diseases [C] - Cancer [C04]
 
 
NCT04616196 / 2021-002177-25: Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Completed
1/2
25
US
NKTR-255, Cetuximab, Erbitux®
Nektar Therapeutics, Nektar Therapeutics
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Cervical Cancer
03/23
03/23
NCT04136756: NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Completed
1
30
US
NKTR-255, NKTR-255 Q21, Rituximab, RITUXAN(R), Daratumumab, DARZALEX FASPRO(TM)
Nektar Therapeutics
Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
04/23
04/23
NCI-2022-02316, NCT05359211: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recruiting
1
24
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Liso-cel, Polymer-conjugated IL-15 Receptor Agonist NKTR-255, IL-15 Receptor Agonist NKTR-255, Long-acting Polymer-conjugated IL-15, NKTR 255, NKTR-255, NKTR255, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Synchronized Multigated Acquisition Scanning, RNVG, SYMA Scanning, Bone Marrow Biopsy, Biopsy of Bone Marrow, Bone Marrow Aspiration, Lumbar Puncture, LP, spinal tap, Computed Tomography, CAT Scan, Computed Axial Tomography, CT, CT SCAN, Positron Emission Tomography, PET, PET scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Biospecimen Collection, Biological Sample Collection, Biopsy, Bx
Fred Hutchinson Cancer Center, Nektar Therapeutics
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
12/24
12/25
IRB-41382, NCT03233854: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Active, not recruiting
1
56
US
Chimeric Antigen Receptor T-Cell Therapy, CAR T-cell therapy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Questionnaire Administration, NKTR-255
Crystal Mackall, MD, California Institute for Regenerative Medicine (CIRM)
B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive
09/25
09/35
NCT05676749: C-TIL051 in Non-Small Cell Lung Cancer

Recruiting
1
20
US
C-TIL051, Pembrolizumab, NKTR-255
AbelZeta, Inc., Nektar Therapeutics
Metastatic Non Small Cell Lung Cancer
03/26
08/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
avipendekin pegol (NKTR-255) / Nektar Therap
NCT05664217: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Terminated
2/3
15
US
NKTR-255 at 1.5 µg/kg, Polymer-conjugated interleukin (IL)-15 Receptor Agonist, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg, Placebo Comparator
Nektar Therapeutics
Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
05/24
08/24
2021-003669-36: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Not yet recruiting
2
280
Europe
BAVENCIO, sacituzumab govitecan, MSB0010718C, IMMU-132, M6223, NKTR-255, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, BAVENCIO, Trodelvy
Merck Healthcare KGaA, MERCK KGAA, Merck Healthcare KGaA
Advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy., Bladder cancer, Diseases [C] - Cancer [C04]
 
 
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
06/25
07/26
RESCUE, NCT05632809: REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors

Recruiting
2
39
US
NKTR-255, Durvalumab
M.D. Anderson Cancer Center, Nektar Therapeutics
Lung Cancer
12/25
12/27
2021-002177-25: A study on NKTR-255 in combination with Cetuximab as salvage treatment for Solid Tumors Estudio sobre NKTR-255 en combinación con Cetuximab como tratamiento de rescate para tumores sólidos.

Not yet recruiting
1/2
78
Europe
NKTR-255, cetuximab, NKTR-255, Lyophilisate for solution for infusion, Solution for infusion, Erbitux
Nektar Therapeutics, NEKTAR THERAPEUTICS, Nektar Therapeutics
Relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC) Carcinoma escamoso de cabeza y cuello (CECC) o carcinoma colorrectal (CCR) recidivante o resistente (R/R), Head and neck squamous cell cancer or colorectal cancer which has spread to other part of body Cáncer epidermoide de cabeza y cuello o cáncer colorrectal que se ha extendido a otra parte del cuerpo, Diseases [C] - Cancer [C04]
 
 
NCT04616196 / 2021-002177-25: Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Completed
1/2
25
US
NKTR-255, Cetuximab, Erbitux®
Nektar Therapeutics, Nektar Therapeutics
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Cervical Cancer
03/23
03/23
NCT04136756: NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Completed
1
30
US
NKTR-255, NKTR-255 Q21, Rituximab, RITUXAN(R), Daratumumab, DARZALEX FASPRO(TM)
Nektar Therapeutics
Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
04/23
04/23
NCI-2022-02316, NCT05359211: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recruiting
1
24
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Liso-cel, Polymer-conjugated IL-15 Receptor Agonist NKTR-255, IL-15 Receptor Agonist NKTR-255, Long-acting Polymer-conjugated IL-15, NKTR 255, NKTR-255, NKTR255, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Synchronized Multigated Acquisition Scanning, RNVG, SYMA Scanning, Bone Marrow Biopsy, Biopsy of Bone Marrow, Bone Marrow Aspiration, Lumbar Puncture, LP, spinal tap, Computed Tomography, CAT Scan, Computed Axial Tomography, CT, CT SCAN, Positron Emission Tomography, PET, PET scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Biospecimen Collection, Biological Sample Collection, Biopsy, Bx
Fred Hutchinson Cancer Center, Nektar Therapeutics
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
12/24
12/25
IRB-41382, NCT03233854: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Active, not recruiting
1
56
US
Chimeric Antigen Receptor T-Cell Therapy, CAR T-cell therapy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Questionnaire Administration, NKTR-255
Crystal Mackall, MD, California Institute for Regenerative Medicine (CIRM)
B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive
09/25
09/35
NCT05676749: C-TIL051 in Non-Small Cell Lung Cancer

Recruiting
1
20
US
C-TIL051, Pembrolizumab, NKTR-255
AbelZeta, Inc., Nektar Therapeutics
Metastatic Non Small Cell Lung Cancer
03/26
08/27

Download Options